AIDS Research and Treatment / 2012 / Article / Tab 2

Clinical Study

Short-Term Rationing of Combination Antiretroviral Therapy: Impact on Morbidity, Mortality, and Loss to Follow-Up in a Large HIV Treatment Program in Western Kenya

Table 2

Cox proportional (unadjusted and adjusted) hazard ratios for predictors of cart initiation.

CovariateUnivariate analysisMultivariate analysisb
Unadjusted hazard ratio95% confidence interval (CI) value Adjusted hazard ratio (AHR)95% Confidence interval (CI) value

Enrolled in the cap period0.860.82, 0.90<0.0010.870.83, 0.92<0.001
Use of Cotrimoxazole or Dapsonea3.222.98, 3.48<0.0012.081.89, 2.29<0.001
On TB treatmenta0.770.73, 0.82<0.0010.600.56, 0.64<0.001
Male gender1.131.08, 1.19<0.0011.141.09, 1.21<0.001
Age (per year increase)a1.001.00, 1.000.1001.001.00, 1.000.950
CD4 (per cell increase)a0.9950.994, 0.995<0.0010.9950.995, 0.996<0.001
WHO Stage Ia1.001.00
WHO Stage IIa1.161.07, 1.26<0.0011.081.00, 1.170.053
WHO Stage IIIa0.890.83, 0.950.0011.201.11, 1.29<0.001
WHO Stage IVa1.331.20, 1.46<0.0011.861.67, 2.07<0.001
Urban Clinica1.030.99, 1.090.1621.061.01, 1.110.030
Travel time < 30 min1.001.00
Travel time 30–60 min1.020.96, 1.090.4940.990.93, 1.060.749
Travel time 1-2 hr1.050.98, 1.120.1510.990.92, 1.060.742
Travel time > 2 hr1.111.03, 1.200.0081.050.97, 1.140.246

aAt Enrollment.
bAdjusted for all covariates.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.